Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

James D. Finklea; Rita Hollaway; Karen Lowe; Francesca Lee; Jade Le; Raksha Jain

doi:10.1016/j.diagmicrobio.2018.05.002

Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

James D. Finklea, Rita Hollaway, Karen Lowe, Francesca Lee, Jade Le, Raksha Jain

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.

Original language	English (US)
Pages (from-to)	75-77
Number of pages	3
Journal	Diagnostic Microbiology and Infectious Disease
Volume	92
Issue number	1
DOIs	https://doi.org/10.1016/j.diagmicrobio.2018.05.002
State	Published - Sep 2018

Keywords

Antibiotic
Cystic fibrosis
Pseudomonas
Susceptibility
beta-Lactam

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2018.05.002

Cite this

@article{d1ad9b470f334ee39fa43fda739b3fc2,

title = "Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients",

abstract = "Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.",

keywords = "Antibiotic, Cystic fibrosis, Pseudomonas, Susceptibility, beta-Lactam",

author = "Finklea, {James D.} and Rita Hollaway and Karen Lowe and Francesca Lee and Jade Le and Raksha Jain",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = sep,

doi = "10.1016/j.diagmicrobio.2018.05.002",

language = "English (US)",

volume = "92",

pages = "75--77",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

AU - Finklea, James D.

AU - Hollaway, Rita

AU - Lowe, Karen

AU - Lee, Francesca

AU - Le, Jade

AU - Jain, Raksha

PY - 2018/9

Y1 - 2018/9

N2 - Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.

AB - Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.

KW - Antibiotic

KW - Cystic fibrosis

KW - Pseudomonas

KW - Susceptibility

KW - beta-Lactam

UR - http://www.scopus.com/inward/record.url?scp=85048497938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048497938&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2018.05.002

DO - 10.1016/j.diagmicrobio.2018.05.002

M3 - Article

C2 - 29884565

AN - SCOPUS:85048497938

SN - 0732-8893

VL - 92

SP - 75

EP - 77

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 1

ER -

Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this